title: Pimozide Inhibits the AcrAB-TolC Efflux Pump in Escherichia coli.
abstract: Efflux pump inhibitors (EPIs) are attractive compounds to reverse multidrug-resistance in clinically relevant bacterial pathogens. In this study we tested the ability of the neuroleptic drug pimozide to inhibit the Escherichia coli AcrAB-TolC efflux pump, whose overproduction confers resistance to various antimicrobial agents. A real-time Nile red efflux assay in the AcrAB - overproducing strain 3-AG100 revealed that pimozide was capable of full inhibition of this pump at a concentration of 100 µM, which is far below its intrinsic MIC (>1mM). However, MIC assay demonstrated very little effect of pimozide with regard to reduction in MICs of various antimicrobial compounds. Only oxacillin MICs were reduced twofold in the presence of pimozide at 100 and 200 µM. Since pimozide did considerably enhance accumulation of ethidium bromide in a fluorescence assay, ethidium bromide MIC assays in the presence and absence of this putative EPI were performed. They revealed that pimozide was able to reduce the MICs of ethidium bromide by 4-fold. In line with previous reports we suggest that the capability of EPIs to restore the susceptibility to antimicrobial agents can be highly substrate-specific due to different substrate binding sites.
authors.affiliation: Center for Infectious Diseases and Travel Medicine, University Hospital, and Department of Medicine, Albert-Ludwigs-University, Freiburg, Germany.
authors.forename: Jürgen A
authors.initials: JA
authors.lastname: Bohnert
authors.forename: Sabine
authors.initials: S
authors.lastname: Schuster
authors.forename: Winfried V
authors.initials: WV
authors.lastname: Kern
keywords: AcrB; efflux pump inhibitor; multidrug resistance; pimozide.
references.citation: Nature. 2000 Jun 22;405(6789):914-9
references.pmid: 10879525
references.citation: Antimicrob Agents Chemother. 2005 Feb;49(2):849-52
references.pmid: 15673787
references.citation: Antimicrob Agents Chemother. 2001 May;45(5):1467-72
references.pmid: 11302812
references.citation: Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6559-65
references.pmid: 20212112
references.citation: Proc Natl Acad Sci U S A. 2012 Apr 10;109(15):5687-92
references.pmid: 22451937
references.citation: Antimicrob Agents Chemother. 2000 Apr;44(4):814-20
references.pmid: 10722475
references.citation: Mol Microbiol. 2010 Oct;78(2):320-30
references.pmid: 20804453
references.citation: In Vivo. 2010 Sep-Oct;24(5):751-4
references.pmid: 20952744
references.citation: Antimicrob Agents Chemother. 2001 Jan;45(1):105-16
references.pmid: 11120952
references.citation: J Antimicrob Chemother. 2011 Sep;66(9):2057-60
references.pmid: 21700628
references.citation: Nature. 2011 Nov 27;480(7378):565-9
references.pmid: 22121023
references.citation: Science. 2006 Sep 1;313(5791):1295-8
references.pmid: 16946072
references.citation: J Med Chem. 1999 Dec 2;42(24):4928-31
references.pmid: 10585202
references.citation: Nature. 2006 Sep 14;443(7108):173-9
references.pmid: 16915237
references.citation: J Bacteriol. 2008 Dec;190(24):8225-9
references.pmid: 18849422
references.citation: Antimicrob Agents Chemother. 2010 Sep;54(9):3770-5
references.pmid: 20606071
references.citation: Int J Antimicrob Agents. 2008 Mar;31(3):198-208
references.pmid: 18180147
references.citation: PLoS One. 2011;6(6):e21196
references.pmid: 21698261
references.citation: Structure. 2006 Mar;14(3):577-87
references.pmid: 16531241
references.citation: J Bacteriol. 2009 Mar;191(6):1729-37
references.pmid: 19060146